ESTRO 2025 - Abstract Book

S1292

Clinical - Lung

ESTRO 2025

Conclusion: Omitting CTV margins in SBRT for NSCLC can negatively impact LC, particularly when coverage of a (hypothetical) CTV margin with BED ≥100 Gy is insufficient.

Keywords: Lung SBRT, Early stage NSCLC

213

Digital Poster Individual participant data meta-analysis (IPDMA) and systematic review of radical radiotherapy in oligometastatic Nonsmall cell lung carcinoma(NSCLC) Ajay Kumar Kondeti 1 , Krishna Tiwari 2 , Muhammad Aaqib Shamim 2 , Naveen Dutt 3 , Pramod Kumar 4 , Isha Yadav 2 , Rakesh Dodiya 2 , Pradeep Dwivedi 2 , Surjit Singh 2 , Shoban Babu Varthya 2 1 Radiation Oncology, AIIMS, Mangalagiri, Mangalagiri, India. 2 Pharmacology, AIIMS, Jodhpur, Jodhpur, India. 3 Pulmonary Medicine, AIIMS, Jodhpur, Jodhpur, India. 4 Medical Oncology, AIIMS, Jodhpur, Jodhpur, India Purpose/Objective: The role of radical radiotherapy in oligometastatic non-small cell lung cancer (NSCLC) is rapidly evolving but has shown mixed results. Hence, the objective of this study is to provide updated, robust, and interpretable estimates on the comparison of add-on radical radiotherapy versus standard therapy alone in oligometastatic NSCLC. Material/Methods: In this systematic review and individual participant data (IPD) meta-analysis, we screened four databases i.e, Medline, Embase, Scopus and Cochrane CENTRAL, until 2024/08/06 for randomized controlled trials (RCTs) comparing add-on radical radiotherapy versus systemic therapy alone in oligometastatic NSCLC furnishing data on overall survival (OS), progression-free survival (PFS), or safety. We retrieved IPD from survival curves of published reports and used one stage IPD meta-analysis. We also estimated the more clinically intuitive restricted mean survival time difference (RMSTD). We assessed between-study heterogeneity using the median hazard ratio (MHR). We rated the evidence certainty using the GRADE framework. Protocol: PROSPERO (CRD42024576829)